Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal polysaccharide diphtheria toxoid conjugate + diphtheria and tetanus toxoids and acellular pertussis adsorbed
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a combination of two vaccines: a quadrivalent meningococcal polysaccharide vaccine conjugated to diphtheria or tetanus toxoid (such as Menactra), plus a combined vaccine containing diphtheria and tetanus toxoids with acellular pertussis components (such as Infanrix or Pediacel). The meningococcal component induces immunity against *Neisseria meningitidis* serogroups A, C, Y, and W-135 by stimulating antibody production through presentation of capsular polysaccharides covalently linked to a carrier protein (diphtheria or tetanus toxoid)[1][3][4]. The DTaP component provides protection against *Corynebacterium diphtheriae* (diphtheria), *Clostridium tetani* (tetanus), and *Bordetella pertussis* (pertussis/whooping cough) by inducing antibodies against their respective toxins[8]. These vaccines are used for active immunization in children to prevent invasive diseases caused by these pathogens. They are often co-administered in pediatric vaccination schedules[8].
- Brand names
- MenactraInfanrixPediacel
- Other names
- meningococcal (groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccinediphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed
02
Targets
Diphtheria toxinNeisseria meningitidis capsular polysaccharide
Beyond the preview
Go deeper on meningococcal polysaccharide diphtheria toxoid conjugate + diphtheria and tetanus toxoids and acellular pertussis adsorbed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal polysaccharide diphtheria toxoid conjugate + diphtheria and tetanus toxoids and acellular pertussis adsorbed.